Abstract
Seventeen patients with advanced melanoma and no prior exposure to chemotherapy were treated with brequinar sodium as first-line chemotherapy. Brequinar was given at a median weekly dose of 1200 mg/m2 intravenously. In 14 patients evaluable for efficacy, there were no objective responses. The toxicity was moderate. We conclude that, at this dose and schedule, brequinar has no activity in advanced melanoma.
Publication types
-
Clinical Trial
-
Clinical Trial, Phase II
-
Multicenter Study
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adult
-
Aged
-
Antineoplastic Agents / adverse effects
-
Antineoplastic Agents / therapeutic use*
-
Biphenyl Compounds / adverse effects
-
Biphenyl Compounds / therapeutic use*
-
Female
-
Humans
-
Male
-
Melanoma / drug therapy*
-
Middle Aged
Substances
-
Antineoplastic Agents
-
Biphenyl Compounds
-
brequinar